Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01653470
Title Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

triple-receptor negative breast cancer

Advanced Solid Tumor

Therapies

Carboplatin

Fluorouracil + Irinotecan + Leucovorin

BMS-906024

Paclitaxel

Age Groups: adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Usc/Norris Comprehensive Cancer Center Los Angeles California 90033 United States Details
Local Institution Brussels 1000 Belgium Details
Local Institution Edmonton Alberta T6G 1Z2 Canada Details
Local Institution Toronto Ontario M5G 2M9 Canada Details
Local Institution Ottawa Quebec K1H 8L6 Canada Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field